Helicobacter pylori infection as a risk factor for gastrointestinal symptoms in patients using aspirin to prevent ischaemic heart disease (English)
- New search for: Laheij, R. J. F.
- New search for: Jansen, J. B. M. J.
- New search for: Verbeek, A. L. M.
- New search for: Verheugt, F. W. A.
- New search for: Laheij, R. J. F.
- New search for: Jansen, J. B. M. J.
- New search for: Verbeek, A. L. M.
- New search for: Verheugt, F. W. A.
In:
Alimentary Pharmacology & Therapeutics
;
15
, 7
;
1055-1059
;
2001
- Article (Journal) / Electronic Resource
-
Title:Helicobacter pylori infection as a risk factor for gastrointestinal symptoms in patients using aspirin to prevent ischaemic heart disease
-
Contributors:Laheij, R. J. F. ( author ) / Jansen, J. B. M. J. ( author ) / Verbeek, A. L. M. ( author ) / Verheugt, F. W. A. ( author )
-
Published in:Alimentary Pharmacology & Therapeutics ; 15, 7 ; 1055-1059
-
Publisher:
- New search for: Blackwell Science Ltd
-
Publication date:2001-07-09
-
Size:5 pages
-
ISSN:
-
DOI:
-
Type of media:Article (Journal)
-
Type of material:Electronic Resource
-
Language:English
-
Source:
Table of contents – Volume 15, Issue 7
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 887
-
The pharmacology of the internal anal sphincter and new treatments of ano‐rectal disordersCook, T. A. / Brading, A. F. / Mortensen, N. J. McC. et al. | 2001
- 899
-
Photodynamic therapy and the alimentary tractSelvasekar, C. R. / Birbeck, N. / Mcmillan, T. / Wainwright, M. / Walker, S. J. et al. | 2001
- 917
-
Proton pump inhibitors versus H2‐antagonists: a meta‐analysis of their efficacy in treating bleeding peptic ulcerGisbert, J. P. / González, L. / Calvet, X. / Roqué, M. / Gabriel, R. / Pajares, J. M. et al. | 2001
- 927
-
The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6‐month, randomized, double‐blind, placebo‐controlled study of efficacy and safetyVakil, N. B. / Shaker, R. / Johnson, D. A. / Kovacs, T. / Baerg, R. D. / Hwang, C. / D'Amico, D. / Hamelin, B. et al. | 2001
- 937
-
The pharmacokinetics of the novel promotile drug, tegaserod, are similar in healthy subjects—male and female, elderly and youngAppel‐Dingemanse, S. / Horowitz, A. / Campestrini, J. / Osborne, S. / Mcleod, J. et al. | 2001
- 945
-
Healthcare resource utilization in the management of oesophageal adenocarcinomaSoni, A. / Sonnenberg, A. et al. | 2001
- 953
-
High‐dose prolonged combination therapy in non‐responders to interferon monotherapy for chronic hepatitis CDi Marco, V. / Vaccaro, A. / Ferraro, D. / Alaimo, G. / Rodolico, V. / Parisi, P. / Peralta, S. / Di Stefano, R. / Almasio, P. L. / Craxì, A. et al. | 2001
- 959
-
Characteristics of patients with irritable bowel syndrome recruited from three sources: implications for clinical trialsLongstreth, G. F. / Hawkey, C. J. / Mayer, E. A. / Jones, R. H. / Naesdal, J. / Wilson, I. K. / Peacock, R. A. / Wiklund, I. K. et al. | 2001
- 965
-
Octreotide 24‐h prophylaxis in patients at high risk for post‐ERCP pancreatitis: results of a multicenter, randomized, controlled trialTestoni, P. A. / Bagnolo, F. / Andriulli, A. / Bernasconi, G. / Crotta, S. / Lella, F. / Lomazzi, A. / Minoli, G. / Natale, C. / Prada, A. et al. | 2001
- 973
-
Impaired bioavailability of vitamin A in adults and children with persistent diarrhoea in ZambiaKelly, P. / Musuku, J. / Kafwembe, E. / Libby, G. / Zulu, I. / Murphy, J. / Farthing, M. J. G. et al. | 2001
- 981
-
Reliability and validity of the digestive health status instrument in samples of community, primary care, and gastroenterology patientsShaw, M. J. / Beebe, T. J. / Adlis, S. A. / Talley, N. J. et al. | 2001
- 989
-
Expression of hepatocyte growth factor, transforming growth factor alpha, apoptosis related proteins Bax and Bcl‐2, and gastrin in human gastric cancerKonturek, P. C. / Konturek, S. J. / Sulekova, Z. / Meixner, H. / Bielanski, W. / Starzynska, T. / Karczewska, E. / Marlicz, K. / Stachura, J. / Hahn, E. G. et al. | 2001
- 1001
-
The Loiano‐Monghidoro population‐based study of Helicobacter pylori infection: prevalence by 13C‐urea breath test and associated factorsBazzoli, F. / Palli, D. / Zagari, R. M. / Festi, D. / Pozzato, P. / Nicolini, G. / Masala, G. / Fossi, S. / Ricciardiello, L. / Panuccio, D. et al. | 2001
- 1009
-
Economic analysis of four triple regimens for the treatment of Helicobacter pylori‐related peptic ulcer disease in in‐patient and out‐patient settings in Hong KongYou, J. H. S. / Lee, K. K. C. / Ho, S. S. S. / Sung, J. J. Y. / Kung, N. N. S. / Yung, M. / Lee, C. / Yee, G. C. et al. | 2001
- 1017
-
Ranitidine bismuth citrate‐based triple therapies after failure of the standard ‘Maastricht triple therapy’: a promising alternative to the quadruple therapy?Perri, F. / Villani, M. R. / Quitadamo, M. / Annese, V. / Niro, G. A. / Andriulli, A. et al. | 2001
- 1023
-
Predictors of failure of Helicobacter pylori eradication with the standard ‘Maastricht triple therapy’Perri, F. / Villani, M. R. / Festa, V. / Quitadamo, M. / Andriulli, A. et al. | 2001
- 1031
-
Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazolePilotto, A. / Franceschi, M. / Leandro, G. / Bozzola, L. / Rassu, M. / Soffiati, G. / Di Mario, F. / Valerio, G. et al. | 2001
- 1037
-
Is a one‐week course of triple anti‐Helicobacter pylori therapy sufficient to control active duodenal ulcer?Tepeš, B. / Križman, I. / Gorenšek, M. / Gubina, M. / Orel, I. et al. | 2001
- 1047
-
Arrest of chronic acid suppressant drug use after successful Helicobacter pylori eradication in patients with peptic ulcer disease: a six‐month follow‐up studyHurenkamp, G. J. B. / Grundmeijer, H. G. L. M. / Van Der Ende, A. / Tytgat, G. N. J. / Assendelft, W. J. J. / Van Der Hulst, R. W. M. et al. | 2001
- 1055
-
Helicobacter pylori infection as a risk factor for gastrointestinal symptoms in patients using aspirin to prevent ischaemic heart diseaseLaheij, R. J. F. / Jansen, J. B. M. J. / Verbeek, A. L. M. / Verheugt, F. W. A. et al. | 2001
- 1061
-
Modified seven‐day, quadruple therapy as a first line Helicobacter pylori treatmentCalvet, X. / Garcia, N. / Gené, E. / Campo, R. / Brullet, E. / Sanfeliu, I. et al. | 2001
- 1067
-
What is the optimal length of proton pump inhibitor‐based triple therapies for H. pylori? A cost‐effectiveness analysisCalvet, X. / Gené, E. / LÓpez, T. / Gisbert, J. P. et al. | 2001
- 1077
-
Comparison of the effects of concanavalin‐A and epidermal growth factor on epithelial cell proliferation in the rat intestineFitzgerald, A. J. / Jordinson, M. / Rhodes, J. M. / Singh, R. / Calam, J. / Goodlad, R. A. et al. | 2001
- 1085
-
Potential gastrointestinal effects of long‐term acid suppression with proton pump inhibitorsNeal, Keith / Logan, Richard et al. | 2001
- 1085
-
Reply–potential gastrointestinal effects of longterm acid suppression with proton pump inhibitorsLaine, Loren et al. | 2001